Sign up for the QMED & MD+DI Daily newsletter.
FDA Panel Backs Medtronic StentFDA Panel Backs Medtronic Stent
An FDA advisory panel yesterday recommended that the agency approve Endeavor, Medtronic's entry into the drug-eluting stent sweepstakes, the Star-Ledger of Newark, NJ reports. Despite some data showing it is more associated with blood clots than Boston Scientific's Taxus, it has a better overall safety profile than Taxus or Johnson & Johnson's Cypher, the panel found. But how much reward will Medtronic reap?
October 11, 2007
1 Min Read
.svg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale "MDDI")
When drug-eluting stents were being developed and when they were first introduced, it was believed the market for them would be huge. But then studies questioning their safety started popping up, and the market shrunk. Even if Medtronic's stent is approved and adopted by some doctors, will it be enough to justify the effort and expense? Especially when Abbott's Xience joins the field?
You May Also Like
.png?width=300&auto=webp&quality=80&disable=upscale)
_(2).png?width=300&auto=webp&quality=80&disable=upscale)